TY - JOUR
T1 - See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions
AU - Cárdenas-Turanzas, Marylou
AU - Follen, Michele
AU - Benedet, John Louis
AU - Cantor, Scott B.
N1 - Funding Information:
We thank Lore Feldman, Richard Zwelling, and Charissa Higginbotham for their editorial contributions. Financial support for this Review was provided by grant PO1-CA82710 from the US National Cancer Institute.
PY - 2005/1/1
Y1 - 2005/1/1
N2 - In a see-and-treat protocol, patients referred for colposcopy because of an abnormal Pap smear in cervical-cancer screening can be treated by loop excision, without biopsy, during one visit to the clinic. However, overtreatment in the see-and-treat strategy has been reported to be 1·2-83·3% for low-grade squamous intraepithelial lesions (SIL) and to be 13·3-83·3% for high-grade SIL. Range of overtreatment narrowed to 4·0-23·5% for those with normal pathology and to 18·0-29·4% for those with normal or low-grade pathology when calculation of overtreatment was restricted to patients diagnosed with high-grade SIL on colposcopy and referral Pap smear. Most common treatment complications are bleeding and infection. Nonetheless, the strategy has become accepted internationally: low costs, decreased patient anxiety, and increased compliance make it appealing, especially in settings with limited health resources, and for patients at risk of not being treated in a timely manner or of not returning for a second appointment. Mathematical modelling may give information about the appropriateness and usefulness of this treatment while the results of long-term clinical trials are awaited.
AB - In a see-and-treat protocol, patients referred for colposcopy because of an abnormal Pap smear in cervical-cancer screening can be treated by loop excision, without biopsy, during one visit to the clinic. However, overtreatment in the see-and-treat strategy has been reported to be 1·2-83·3% for low-grade squamous intraepithelial lesions (SIL) and to be 13·3-83·3% for high-grade SIL. Range of overtreatment narrowed to 4·0-23·5% for those with normal pathology and to 18·0-29·4% for those with normal or low-grade pathology when calculation of overtreatment was restricted to patients diagnosed with high-grade SIL on colposcopy and referral Pap smear. Most common treatment complications are bleeding and infection. Nonetheless, the strategy has become accepted internationally: low costs, decreased patient anxiety, and increased compliance make it appealing, especially in settings with limited health resources, and for patients at risk of not being treated in a timely manner or of not returning for a second appointment. Mathematical modelling may give information about the appropriateness and usefulness of this treatment while the results of long-term clinical trials are awaited.
UR - http://www.scopus.com/inward/record.url?scp=11844250595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11844250595&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(04)01712-7
DO - 10.1016/S1470-2045(04)01712-7
M3 - Review article
C2 - 15629275
AN - SCOPUS:11844250595
SN - 1470-2045
VL - 6
SP - 43
EP - 50
JO - Lancet Oncology
JF - Lancet Oncology
IS - 1
ER -